News
- Author:
- Ted Bosworth
Publish date: October 5, 2021
There was a clear dose effect; hair growth increased more quickly with the 4-mg dose of baricitinib than with the 2-mg dose.
News
- Author:
- Ted Bosworth
Publish date: October 5, 2021
These findings not only include substantial clinical efficacy but good tolerability with “no serious treatment-related adverse events.”
News
- Author:
- Ted Bosworth
Publish date: October 4, 2021
“Swift and aggressive treatment is required to avoid irreversible changes.”
News
- Author:
- Ted Bosworth
Publish date: October 4, 2021
“This is likely to be very useful in patients who are looking for a topical therapy for skin folds or the face, where there is a need for well-tole...
News
- Author:
- Ted Bosworth
Publish date: October 4, 2021
The incidence of prurigo pigmentosa, which might most affect patients of Asian heritage, is on the rise.
News
- Author:
- Ted Bosworth
Publish date: October 1, 2021
“Deucravacitinib is very distinct from the other JAK inhibitors, and I think we are seeing this in the clinical studies.”
News
- Author:
- Ted Bosworth
Publish date: September 16, 2021
Four dermatologists tracking standards of beauty in ethnic groups agree that tastes and perceptions have changed.
News
- Author:
- Ted Bosworth
Publish date: September 10, 2021
Due to a steep rise, opioid-associated cardiac arrests have become a major public health issue.
News
- Author:
- Ted Bosworth
Publish date: September 9, 2021
Increasing ED-based interventions and staff trained in addressing emergency mental health needs might help to meet the needs of these patients, sai...
Article
- Author:
- Ted Bosworth
Publish date: September 8, 2021
In this study, unlike some previous studies, children were evaluated longitudinally, rather than in a single point in time.
News
- Author:
- Ted Bosworth
Publish date: September 8, 2021
The new set of ESC/EACTS guidelines for heart valve disease offer more than 45 revised or new recommendations.
News
- Author:
- Ted Bosworth
Publish date: August 30, 2021
Even though PRONOUNCE, a trial comparing prostate cancer drugs for cardiovascular safety couldn’t reach a conclusion, it may prove to be a model.
News
- Author:
- Ted Bosworth
Publish date: August 29, 2021
Fractional flow reserve studies in all patients at time of angiography is not supported by the randomized RIPCORD 2 trial.
News
- Author:
- Ted Bosworth
Publish date: August 28, 2021
A negative clinical trial suggests ablation must be performed at early stages of fibrosis to improve AFib outcomes, but experts are wary of that co...
News
- Author:
- Ted Bosworth
Publish date: August 27, 2021
In patients with modestly reduced left ventricular ejection fraction after MI, implantable monitors detect many times more arrhythmias than usual c...
